In this study, RY103, an IDO1/TDO dual inhibitor, showed excellent therapeutic efficacy via downregulating the IDO1/TDO–Kyn–AhR–AQP4 signal pathway in GL261 orthotopic glioma mice. This evidence concerns the gene AHR and glioma.